We are actively looking for IFAs, wealth managers, brokers and investment professionals to introduce qualified investors to the ReGen Therapeutics Phase 3 Rights Issue. A compelling pre-IPO opportunity, a competitive commission structure and a clear path to listing.
Register your interest →ReGen Therapeutics is merging with Futurum Group, a media and entertainment company with a portfolio of independently valued TV animation IP and a clear pathway to a public listing on AIM or the London Stock Exchange, targeted for later in 2026.
As part of that merger, a Rights Issue has been running for existing ReGen shareholders across Phase 1 and Phase 2. Phase 3 has now been opened to external investors on exactly the same privileged terms, the same discounted entry price, the same bonus shares and the same warrants that existing shareholders have received.
There are already over 1,500 ReGen shareholders registered on the portal and actively engaged in the process. Momentum is building towards the IPO and Phase 3 is the opportunity for new investors, introduced by you, to be part of that journey from here.
Phase 3 of the Rights Issue is now open to external investors at £0.592 per share, a 20% discount to the current market price of £0.74, with bonus shares and warrants on top. The estimated IPO valuation is approximately £100m.
For introducers, this is a pre-packaged, well-documented opportunity with a clear deal structure, a professional investor portal and a team that will support every stage of the introduction process.
Simple, transparent and supported at every stage.
For every client you introduce who goes on to invest in Phase 3, you earn 10% of the value of their investment. There is no cap on the number of introductions you can make and no limit on earnings. Full terms will be set out in your introducer agreement.
Commission examples are illustrative. Full terms confirmed in your introducer agreement. Subject to successful investment completion.
Tell us a little about yourself and your client base. A member of our team will be in touch promptly to discuss the programme and next steps.
A member of our team will be in touch with you shortly to discuss the introducer programme and next steps.
In the meantime, if you have any questions please contact us at
info@regentherapeutics.uk